Study shows efficacy of anti-VEGF therapy in myopic CNV

Based on positive outcomes from the RADIANCE trial, ranibizumab has recently been approved by European authorities as a treatment for patients with choroidal neovascularization (CNV) secondary to pathologic myopia, according to Sebastian Wolf MD.
“The trial data showed that ranibizumab provides rapid and superior improvement in visual acuity compared with the current licensed standard of care, photodynamic therapy with verteporfin after three months. There was an average 14-letter visual acuity gain in the first year with a median of two injections and more than 60 per cent of patients in the study did not need any further injections after six months,” said Dr Wolf.
Tags: intraocular pressure
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.